Angion Completes Enrollment in Phase 2 Study of ANG-3777 for Acute Lung Injury in Patients with COVID-19 Associated Pneumonia
Go back to Angion Completes Enrollment in Phase 2 Study of ANG-3777 for Acute Lung Injury in Patients with COVID-19 Associated Pneumonia| Angeion Corp (NASDAQ: ANGN) | Delayed: 1.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.00 | 52 Week High | $6.10 | |||
| Open | $1.00 | 52 Week Low | $3.80 | |||
| Day High | $1.00 | P/E | N/A | |||
| Day Low | $1.00 | EPS | $-0.10 | |||
| Volume | 22,561 | |||||
